Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis
Lukas A Basedow, Thomas Riemer, Simon Reiche, Reinhold Kreutz, Tomislav Majić
Frontiers in Pharmacology September 16, 2021 DOI: 10.3389/fphar.2021.739966 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and meta-analysis Peer reviewed |
|---|---|
| Sample size | 539 |
| Population | Users of serotonergic psychedelics (ayahuasca, LSD, peyote) and non-user controls |
| Topics | Psilocybin Serotonin |
| Keywords | Neuropsychology Meta-analysis Clinical psychology Systematic review Medline Hallucinogen Cognition |
| Citations | 16 |
| Key findings | No uniform pattern of neuropsychological impairment was found across serotonergic psychedelics; instead, LSD users showed reduced executive functioning, ayahuasca users showed increased executive functioning on one measure, and peyote users showed no differences. |
Abstract
Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In this review and meta-analysis, we investigated if repeated SP use associates with a characteristic neuropsychological profile indicating persisting effects on neuropsychological function.
Methods: We conducted a systematic review of studies investigating the neuropsychological performance in SP users, searching studies in Medline, Web of Science, embase, ClinicalTrials.gov , and EudraCT. Studies were included if they reported at least one neuropsychological measurement in users of SPs. Studies comparing SP users and non-users that reported mean scores and standard deviations were included in an exploratory meta-analysis.
Results: 13 studies (N = 539) published between 1969 and 2020 were included in this systematic review. Overall, we found that only three SPs were specifically investigated: ayahuasca (6 studies, n = 343), LSD (5 studies, n = 135), and peyote (1 study, n = 61). However, heterogeneity of the methodological quality was high across studies, with matching problems representing the most important limitation. Across all SPs, no uniform pattern of neuropsychological impairment was identified. Rather, the individual SPs seemed to be associated with distinct neuropsychological profiles. For instance, one study ( n = 42) found LSD users to perform worse in trials A and B of the Trail-Making task, whereas meta-analytic assessment (5 studies, n = 352) of eleven individual neuropsychological measures indicated a better performance of ayahuasca users in the Stroop incongruent task ( p = 0.03) and no differences in the others (all p > 0.05).
Conclusion: The majority of the included studies were not completely successful in controlling for confounders such as differences in non-psychedelic substance use between SP-users and non-users. Our analysis suggests that LSD, ayahuasca and peyote may have different neuropsychological consequences associated with their use. While LSD users showed reduced executive functioning and peyote users showed no differences across domains, there is some evidence that ayahuasca use is associated with increased executive functioning.
Comparable studies
Other systematic reviews and meta-analyses on serotonin, most cited first.
Citations in the library
Cited by 15
- Psychedelic Cognition—The Unreached Frontier of Psychedelic Science Frontiers in Neuroscience March 15, 2022
- Supportive Touch in Psychedelic Assisted Therapy. The American Journal of Bioethics 2025
- Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality Neuroscience & Biobehavioral Reviews February 3, 2024
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis. Scientific Reports June 26, 2024
- The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action Addiction Biology April 1, 2024
and 10 more in the library
Cites 54
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology October 11, 2017
- Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology May 20, 2016
and 49 more in the library